Constellium (NYSE:CSTM – Get Free Report) is projected to post its Q3 2026 results before the market opens on Wednesday, October 28th. Analysts expect the company to announce earnings of $0.73 per share and revenue of $2.50 billion for the quarter. Individuals may review the information on the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Wednesday, October 28, 2026 at 10:00 AM ET.
Constellium (NYSE:CSTM – Get Free Report) last issued its quarterly earnings data on Wednesday, July 29th. The industrial products company reported $1.04 earnings per share for the quarter, beating the consensus estimate of $0.86 by $0.18. Constellium had a net margin of 5.69% and a return on equity of 51.66%. The firm had revenue of $2.75 billion for the quarter, compared to the consensus estimate of $2.73 billion. During the same period last year, the firm posted $0.25 EPS. Constellium’s quarterly revenue was up 30.7% compared to the same quarter last year. On average, analysts expect Constellium to post $3.79 EPS for the current fiscal year and $2.90 EPS for the next fiscal year.
Constellium Price Performance
Shares of NYSE CSTM opened at $23.34 on Tuesday. The stock has a market cap of $3.16 billion, a P/E ratio of 6.02 and a beta of 1.57. The firm’s 50-day simple moving average is $25.85 and its 200 day simple moving average is $27.78. Constellium has a fifty-two week low of $14.62 and a fifty-two week high of $36.99. The company has a quick ratio of 0.61, a current ratio of 1.43 and a debt-to-equity ratio of 1.50.
Analyst Upgrades and Downgrades
CSTM has been the subject of several research analyst reports. Wall Street Zen downgraded shares of Constellium from a “strong-buy” rating to a “buy” rating in a research report on Saturday, October 17th. Weiss Ratings reissued a “hold (c+)” rating on shares of Constellium in a research note on Monday, September 28th. Deutsche Bank Aktiengesellschaft reduced their target price on Constellium from $39.00 to $36.00 and set a “buy” rating for the company in a report on Thursday, October 8th. Zacks Research cut Constellium from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, October 6th. Finally, Barclays began coverage on Constellium in a report on Wednesday, October 14th. They set an “equal weight” rating and a $28.00 price target on the stock. Four investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $33.33.
View Our Latest Stock Analysis on CSTM
Insiders Place Their Bets
In other news, Director Jean-Christophe Deslarzes bought 1,490 shares of Constellium stock in a transaction that occurred on Monday, August 3rd. The stock was purchased at an average cost of $27.24 per share, with a total value of $40,587.60. Following the completion of the transaction, the director directly owned 43,515 shares in the company, valued at $1,185,348.60. This trade represents a 3.55% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. 1.20% of the stock is currently owned by company insiders.
Constellium Company Profile
Constellium SE (NYSE: CSTM) is a global manufacturer of aluminum products and components. The company develops and produces rolled, extruded and formed aluminum solutions for customers in the aerospace, automotive, packaging, transportation and industrial sectors.
Its products include aerospace plates and sheets, automotive body and structural components, aluminum beverage-can sheet, foil stock, extrusions and other engineered components. Constellium’s offerings are used in aircraft structures, vehicles, beverage and food packaging, rail transportation and various industrial applications.
Constellium was established in 2011 following the acquisition and combination of aluminum products businesses formerly associated with Alcan.
Read More
- Five stocks we like better than Constellium
- Comfort Systems Earnings: AI Slowdown or More Growth Ahead?
- Bristol Myers Squibb’s Cancer Breakthrough Could Have Implications Beyond Its Own Stock
- 5 Beaten-Down Growth Stocks Trading Like Value Plays as Cash Chases Mega-Caps
- Anthropic’s IPO Filing Reveals a Massive Opportunity for AI Infrastructure Giants
Receive News & Ratings for Constellium Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Constellium and related companies with MarketBeat.com's FREE daily email newsletter.
